Incretin-based therapy: renal effects
Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...
Saved in:
| Main Authors: | Anton Ivanovich Korbut, Vadim Valerievich Klimontov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2016-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/7727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
by: Arunkumar Krishnan, et al.
Published: (2024-12-01) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01) -
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01) -
Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology
by: Bhaskar Pal, et al.
Published: (2024-01-01) -
Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)